JTO Clinical and Research Reports : Impact Factor & More
eISSN: 2666-3643
Open AccessShare this on:
Key Metrics
CiteScore 
1
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on JTO Clinical and Research Reports
JTO Clinical and Research Reports Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | USD 2000 |
| Publication Time | 19 |
| Editorial Review Process | Blind peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | International Association for the Study of Lung Cancer |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in JTO Clinical and Research Reports ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in JTO Clinical and Research Reports
Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.
- 1 Aug 2026
- JTO clinical and research reports
Rare ALK Fusions in NSCLC – Expanding the Boundaries of Precision Oncology
- 1 Jul 2026
- JTO Clinical and Research Reports
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.
- 1 Jul 2026
- JTO clinical and research reports
Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion\u2013Positive NSCLC Real-World Cohort: A Brief Report
- 15 Jun 2026
- JTO Clinical and Research Reports
Biopsies Can Predict Lung Adenocarcinoma IASLC Grade: A New Proposal and Grading Pitfalls
- 5 Jun 2026
- JTO Clinical and Research Reports
Prophylactic Cranial Irradiation and Survival in Limited-Stage SCLC: A Multicenter Real-World Analysis From the Canadian SCLC Database (CASCADE)
- 1 Jun 2026
- JTO Clinical and Research Reports
Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.
- 1 Aug 2026
- JTO clinical and research reports
Rare ALK Fusions in NSCLC – Expanding the Boundaries of Precision Oncology
- 1 Jul 2026
- JTO Clinical and Research Reports
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.
- 1 Jul 2026
- JTO clinical and research reports
Clinical Activity of RET TKI Plus Chemotherapy After Progression on a RET TKI in a RET Fusion\u2013Positive NSCLC Real-World Cohort: A Brief Report
- 15 Jun 2026
- JTO Clinical and Research Reports
Biopsies Can Predict Lung Adenocarcinoma IASLC Grade: A New Proposal and Grading Pitfalls
- 5 Jun 2026
- JTO Clinical and Research Reports
Prophylactic Cranial Irradiation and Survival in Limited-Stage SCLC: A Multicenter Real-World Analysis From the Canadian SCLC Database (CASCADE)
- 1 Jun 2026
- JTO Clinical and Research Reports
FAQs on JTO Clinical and Research Reports
How many articles did JTO Clinical and Research Reports publish last year? 
What is Citescore for JTO Clinical and Research Reports?
Who is the publisher of JTO Clinical and Research Reports?
